echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Phase III pivotal clinical IND of IMG-020 was accepted by CDE

    The Phase III pivotal clinical IND of IMG-020 was accepted by CDE

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 23, Chuangxiang Bio announced that the Center for Drug Evaluation (CDE) of the State Drug Administration has officially accepted the IND application of its candidate drug izokibep (IMG-020) for the treatment of plaque psoriasis.


    Izokibep is jointly developed by Chuangxiang and its partners Sweden Affibody AB (hereinafter referred to as "Affibody") and American ACELYRIN, INC.


    Chuangxiang is responsible for leading and organizing the design, submission and development of global clinical studies for indications such as psoriasis, ankylosing spondylitis and Takayasu arteritis


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.